Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes

Nutrition and Diabetes

Volumn 1, Issue 1, 2011, Pages

  Wagner, I V ^a   Perwitz, N ^a   Drenckhan, M ^a   Lehnert, H ^a   Klein, J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

adipogenesis; apoptosis; CB1 receptor knockout mice; depot specific effects in adipose tissue; inflammation; transdifferentiation

Indexed keywords

CANNABINOID 1 RECEPTOR; GLUCOSE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOGENESIS; BROWN ADIPOSE TISSUE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; EPIDIDYMIS FAT; GLUCOSE TRANSPORT; INFLAMMATION; INGUINAL REGION; MITOCHONDRION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; THERMOGENESIS; WHITE ADIPOSE TISSUE;

EID: 84884212767     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2011.12     Document Type: Article

References (57)

1. Tiraby C, Langin D. Conversion from white to brown adipocytes: a strategy for the control of fat mass? Trends Endocrinol Metab 2003; 14: 439-441.
2. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D et al. Acquirement of brown fat cell features by human white adipocytes. J Biol Chem 2003; 278: 33370-33376.
3. Perwitz N, Wenzel J, Wagner I, Büning J, Drenckhan M, Zarse K et al. Cannabinoid type 1 receptor blockade induces towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab 2010; 12: 158-166.
4. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005; 37: 270-275.
5. Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006; 38: 356-358.
6. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
7. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
8. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008; 57: 2028-2036.
9. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
10. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 2009; 32: 1068-1075.
11. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S57-S63.
12. Ibrahim M. Subcutaneous and visceral adipose tissue:structural and functional differences. Obes Rev 2010; 1: 11-18.
13. Klein JPPA, Owecki M, Chaldokov GN, Böhm M, Hausman G, Lapiere CM et al. What are subcutaneous adipocytes really good for? Exp Dermatol 2007; 1: 45-70.
14. Tran TT, Kahn CR. Transplantation of adipose tissue and stem cells:role in metabolism and disease. Nat Rev Endocrinol 2010; 4: 195-213.
15. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008; 7: 410-420.
16. Tritos NA, Mantzoros CS. Leptin: its role in obesity and beyond. Diabetologia 1997; 40: 1371-1379.
17. Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 2007; 50: 1127-1139.
18. Ravussin E, Galgani JE. The implication of brown adipose tissue for humans. Annu Rev Nutr 2011; 31: 33-47.
19. Richard DCA, Dore G, Ouellet V, Picard F. Determinants of brown adipocyte development and thermogenesis. Int J Obes 2010; 34: S59-S66.
20. Richard DPF. Brown fat biology and thermogenesis. Front Biosci 2011; 16: 1233-1260.
21. Tews DWM. Renaissance of Brown Adipose Tissue. Horm Res Paediatr 2011; 75: 231-239.
22. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-839.
23. Medina-Gomez G, Gray S, Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 2007; 10: 1132-1137.
24. Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, Wu Z et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med 2001; 7: 1128-1132.
25. Cederberg A, Gronning LM, Ahren B, Tasken K, Carlsson P, Enerback S. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. Cell 2001; 106: 563-573.
26. Seale PKS, Spiegelman B. Transcriptional control of brown adipocyte development and physiological function-of mice and men. Genes Dev 2009; 23: 788-797.
27. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR. Beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 1999; 274: 34795-34802.
28. Klein J, Fasshauer M, Klein HH, Benito M, Kahn CR. Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. Bioessays 2002; 24: 382-388.
29. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
30. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: 57-63.
31. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
32. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone 2006; 8 (Suppl 4): S14-S23.
33. Scheen AJ. Does the metabolic syndrome help to select patients requiring high statin dose? Lancet 2006; 368: 893-894.
34. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
35. Gary-Bobo M, Elachouri G, Scatton B, Le Flur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR 141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F 442A preadipocytes. Mol Pharmacol 2006; 69: 471-478.
36. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
37. Matias IG, Gontheir MP, Orlando P, Martiadis V, De Petrocellis L, Cervico C et al. Regulation, function and dysregulation of endocannabinoids in models of adipose and beta-pencreatic cells and in obesity and hyperglycemia. J Clini Endocrinol Metab 2006; 91: 3171-3180.
38. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Yudkin JS et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 2004; 27: 372-377.
39. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
40. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002; 51: 718-723.
41. Laplante M, Festuccia WT, Soucy G, Gelinas Y, Lalonde J, Berger JP et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006; 55: 2771-2778.
42. Rice SP, Zhang L, Grennan-Jones F, Agarwal N, Lewis MD, Rees DA, Ludgate M. Dehydroepandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Mol Cell Endocrinol 2010; 320: 51-57.
43. Hallenborg PFS, Madsen L, Kristiansen K. The tumor suppressors pRB and p 53 as regulators of adipocyte differentiation and function. Expert Opin Ther Targets 2009; 13: 235-246.
44. Niesler CU SK, Prins JB. Human preadipocytes display a depotspecific susceptibility to apoptosis. Diabetes 1998; 47: 1365-1368.
45. Ambati S, Yang JY, Rayalam S, Park HJ, Della-Ferra MA, Baile CA. Ajoene exerts potent effects in 3T3-L1 adipocytes by inhibiting adipogenesis and inducing apoptosis. Phytother Res 2009; 23: 513-518.
46. Yang JY, D-FM, Baile CA. Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L 1 cells. Obesity (Silver Spring) 2008; 16: 16-22.
47. Park HJ, RS, Della-Ferra MA, Ambati S, Yang JY, Baile CA. Withaferin A induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Biofactors 2008; 33: 137-148.
48. Chon JW, Hwang EJ, Park YK. Chlorella methanol extract reduces lipid accumulation in and increases the number of apoptotic 3T3-L1 cells. Ann NY Acad Sci 2009; 1171: 183-189.
49. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561.
50. Fontana LEJ, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013.
51. Bose T, Alvarenga JC, Tejero ME, Voruganti VS, Proffitt JM, Freeland-Graves JH, Cole SA et al. Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J Med Primatol 2009; 38: 418-424.
52. Van den Oever IA, Numohamed MT, Simsek S. Endothelial dysfunction, inflammation and apoptosis in diabetes mellitus. Mediators Inflamm 2010; 2010: 792393.
53. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010; 59: 926-934.
54. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000; 49: 759-767.
55. Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon YS et al. Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell 2009; 36: 996-1006.
56. Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003; 23: 1085-1094.
57. Stefl B, Janovska A, Hodny Z, Rossmeisl M, Horakova M, Syrovy I et al. Brown fat is essential for cold-induced thermogenesis but not for obesity resistance in aP2-Ucpmice. AmJ Physiol 1998; 274: E527-E533.